60% of Americans live with chronic inflammatory diseases, and it is expected that the prevalence will increase steadily over the next 30 years.1
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.1
Evommune’s focus is the discovery and development of unique therapies that help patients with chronic inflammatory diseases.
Reference: 1. Pahwa R, Goyal A, Bansal P, et al. Chronic Inflammation. StatPearls Publishing. 2020. https://www.ncbi.nlm.nih.gov/books/NBK493173/. Published January 2020. Updated August 10, 2020. Accessed October 7, 2020.
Evommune is using the skin as the lens to uncover new approaches for accelerating the development of vital medicines across immunology and dermatology. Utilizing a novel screening platform, we identify molecules that are differentiated and that have a greater probability of being effective in treating patients.
By recognizing the interdependence of innovation and sustainable healthcare, we strive to develop unique medicines that benefit the patient and deliver significant value.
We utilize a tissue-based screening platform, developed by Evommune scientists, to efficiently evaluate development candidates that have the potential to meet our profile for differentiation. This approach greatly enhances the probability of selecting new molecules that are clinically effective.
Our extensive research and development experience allows us to accelerate all phases of drug development. We are highly accomplished and have a 30-year track record of global regulatory approvals and commercialization of products across multiple therapeutic areas. We have successfully developed small molecules and biologics and have developed drugs in injectable, oral, and topical presentations.
|Program||Proof of Concept
|Discovery||Pre-IND||Phase 1||Phase 2||Phase 3|
|Proof of Concept Indications||Rosacea
|Proof of Concept Indications||Psoriasis|
|Proof of Concept Indications||Pruritus|
|Proof of Concept Indications||Atopic Dermatitis|
Our team has a track record of drug approvals and commercial successes. At Evommune, we are building off our extensive experience to connect disciplines that address inﬂammatory disease. Our dedication to science and innovation drives us in our pursuit to identify, discover, and develop unique and vital medicines.
“Available medicines have made progress treating inflammation, but we know there’s a need for safer, more effective therapies. That’s where Evommune will make a difference—we are committed to science and innovation to improve patients' lives.”
President & CEO, Evommune
President & CEO
Chief Medical Officer
Member of the Board of Directors
Managing Parter at Pivotal bioVenture Partners
Venture Partner at Pivotal Partners
Chairman and Chief Executive Officer at TheraVida, Inc.
Professor Emeritus, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine
Adjunct Clinical Professor (Dermatology), Touro University Nevada
Sol and Clara Kest Professor of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai
Professor, Laboratory Head, The Rockefeller University
Waldman Professor and Chairman, Kimberly and Eric J. Waldman Department of Dermatology, Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai
Professor Emeritus, Department of Dermatology, Medical University of Vienna
We are dedicated to establishing partnerships that support our strategy to drive an innovative development pipeline leading to novel treatments that improve the lives of patients with inflammatory conditions.
We look for the best in our partners, collaborating with those we know will inspire us to achieve greater success together. We are continually evaluating new opportunities and will pursue products from discovery through clinical-stage development.
Contact us to discuss a partnership at: email@example.com
Axcelead is the first integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded the drug discovery research capabilities of Takeda Pharmaceutical Company Limited and started its business on July 1, 2017. The company provides integrated services, from discovery of drug targets to optimization of small- and medium-molecule drug candidates, in which the company has particular expertise, and to the process of bridging the gap to clinical development.
Dermira, a wholly-owned subsidiary of Eli Lilly and Company, is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. We are focused on delivering important new therapies to the millions of patients living with chronic skin conditions.
Dermira is committed to understanding and addressing the needs of both patients and physicians. We are using our experience and insight to identify and develop leading-edge medical dermatology clinical programs. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology.
Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. Pivotal bioVenture invests in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs.
At Evommune, we are passionate about our mission to help people with inﬂammatory diseases. We believe in integrity and personal accountability — qualities that make us good team members, partners, and collaborators. We work hard and take satisfaction in doing it right every time.
We protect our culture and core values. We are:
We value individuals who are not only talented at what they do, but also are meticulous about how they do it. Do you have deep knowledge of your function and have strong emotional intelligence? Are you a professional who is an expert in your ﬁeld and is ready to share your passion? Do you value relationships and the success of your colleagues? If so, reach out to us to discuss working here.
Evommune is an Equal Opportunity Employer and does not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, nondisqualifying physical or mental disability, national origin, veteran status, or any other characteristic protected by applicable law.
Something went wrong, please try again.
Thank you for contacting us. We'll get back to you as soon as possible.